Mobocertinib, also known by its brand name Exkivity, is a targeted therapy medication primarily used to treat patients with non-small cell lung cancer (NSCLC) that has specific mutations in the epidermal growth factor receptor (EGFR). While Mobocertinib has shown significant efficacy in clinical trials, it is essential to be aware of its potential side effects and important precautions to take during treatment.

Mobocertinib Side Effects

Mobocertinib can cause various side effects, ranging from mild to severe. Understanding these side effects is crucial for managing the patient's overall health and ensuring the effectiveness of the treatment.

Common Side Effects

The most common side effects of Mobocertinib include:

• Diarrhea: Patients may experience frequent bowel movements or loose stools. It is recommended to start using antidiarrheal medications like loperamide if diarrhea occurs, and increase fluid and electrolyte intake. Monitor electrolyte levels closely and adjust the dosage of Mobocertinib if necessary.
• Rash: Skin rashes are another common side effect. Patients should keep the skin clean and moisturized to prevent irritation. In severe cases, consult a healthcare provider for appropriate treatment.
• Nausea and Vomiting: These symptoms can be managed with antiemetic medications. If vomiting occurs after taking the medication, do not take an additional dose; wait until the next scheduled dose.
• Oral Mucositis: This condition involves inflammation and ulcers in the mouth. Maintaining good oral hygiene and using prescribed mouth rinses can help alleviate discomfort.
• Appetite Decrease: Patients may experience a loss of appetite, which can lead to weight loss. Encourage a balanced diet and small, frequent meals to maintain nutrition.

Serious Side Effects

Mobocertinib can also cause more severe side effects that require immediate medical attention:

• QTc Prolongation: Mobocertinib can cause a dangerous heart rhythm condition called QTc prolongation, which can lead to torsades de pointes, a type of ventricular tachycardia. Before starting treatment, assess QTc and baseline electrolyte levels, and correct any abnormalities. Regularly monitor QTc and electrolytes during treatment. Avoid using other medications that can prolong QTc.
• Interstitial Lung Disease (ILD) / Pneumonia: Mobocertinib can cause fatal ILD or pneumonia. Monitor patients for new or worsening respiratory symptoms. If ILD or pneumonia is suspected, discontinue Mobocertinib immediately. If confirmed, permanently stop the medication.
• Cardiotoxicity: Mobocertinib can lead to serious heart conditions such as reduced ejection fraction, cardiomyopathy, and congestive heart failure. Regularly monitor heart function, including left ventricular ejection fraction assessments. Adjust the dosage or discontinue the medication based on severity.

Understanding and managing these side effects is crucial for maintaining the patient's quality of life and ensuring the effectiveness of the treatment regimen.

Using Mobocertinib Safely

To ensure the safe and effective use of Mobocertinib, patients and healthcare providers should follow specific guidelines and precautions.

Dosing and Administration

The recommended dose of Mobocertinib is 160 mg taken orally once daily until disease progression or unacceptable toxicity. Take the medication at the same time each day, with or without food. Swallow the capsule whole; do not open, chew, or dissolve its contents. If a dose is missed by more than 6 hours, skip the missed dose and take the next dose at the regular time. If vomiting occurs after taking the medication, do not take an additional dose; wait until the next scheduled dose.

Drug Interactions

Mobocertinib can interact with other medications, potentially affecting its efficacy and safety. Avoid using strong or moderate CYP3A inhibitors, as they can increase Mobocertinib's blood concentration and the risk of adverse reactions, including QTc prolongation. If co-administration with moderate CYP3A inhibitors is unavoidable, reduce the dose of Mobocertinib and monitor QTc intervals more frequently. Similarly, avoid using strong or moderate CYP3A inducers, as they can decrease Mobocertinib's blood concentration and reduce its antitumor activity. If co-administration is necessary, monitor the patient closely and adjust the dosage accordingly.

Patient Monitoring and Follow-Up

Regular monitoring is essential to detect and manage potential side effects and drug interactions. Healthcare providers should:

• Assess QTc and baseline electrolyte levels before starting treatment and regularly during treatment.
• Monitor patients for signs of ILD or pneumonia, such as new or worsening respiratory symptoms.
• Evaluate heart function, including left ventricular ejection fraction, regularly during treatment.
• Monitor for signs of liver toxicity and adjust the dosage or discontinue the medication if necessary.
• Advise patients to report any new or worsening symptoms promptly.

By following these guidelines, patients and healthcare providers can work together to ensure the safe and effective use of Mobocertinib, maximizing its benefits while minimizing potential risks.